The estimated Net Worth of George Siber is at least $1.43 Tausend dollars as of 27 May 2022. George Siber owns over 20,425 units of Genocea Biosciences Inc stock worth over $0 and over the last 11 years he sold GNCA stock worth over $1,430. In addition, he makes $0 as Independent Director at Genocea Biosciences Inc.
George has made over 3 trades of the Genocea Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 20,425 units of GNCA stock worth $1,430 on 27 May 2022.
The largest trade he's ever made was buying 163,400 units of Genocea Biosciences Inc stock on 29 August 2018 worth over $99,674. On average, George trades about 21,560 units every 167 days since 2014. As of 27 May 2022 he still owns at least 252 units of Genocea Biosciences Inc stock.
You can see the complete history of George Siber stock trades at the bottom of the page.
Dr. George R. Siber M.D. serves as Independent Director of the Company. Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines ("Wyeth"). While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines, including: Prevnar, a pneumococcal vaccine which has achieved multibillion dollar revenues; Acel-Imune, an acellular pertussis vaccine; and Meningitec, a meningococcal meningitis vaccine. Prior to Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber led the research and manufacturing of multiple vaccines and immune globulins including Respigam, a human immune globulin against respiratory syncytial virus. Since 2007, Dr. Siber has served on the boards of directors of several vaccine companies, including Crucell, Selecta Biosciences, Vedantra Pharmaceuticals and Affinivax Inc., and as a consultant or scientific advisory board member of ClearPath Vaccines Company, of which he is currently the Chief Scientific Officer, PaxVax, Vaxess Technologies, Inc., the Bill & Melinda Gates Foundation, PATH, the Wellcome Trust, the European Commission (on vaccinations), the National Institutes of Health, or NIH, and the Korean FDA. Dr. Siber serves as a member of the Board of Trustees of the International Vaccine Institute. Dr. Siber holds an M.D. degree from McGill University in Canada, received post-doctoral training in Internal Medicine at Rush-Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and Infectious Disease and vaccinology training at Children’s Hospital and Beth Israel Hospital, Harvard Medical School Boston. Siber’s experience in life sciences and vaccine industries and his experience overseeing the development of multiple vaccines, qualifies him to serve as a member of our Board of Directors.
George Siber is 75, he's been the Independent Director of Genocea Biosciences Inc since 2019. There are no older and 18 younger executives at Genocea Biosciences Inc.
George's mailing address filed with the SEC is 2000 BROADWAY, PENTHOUSE 2B, NEW YORK, NY, 10023.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: